Presentation is loading. Please wait.

Presentation is loading. Please wait.

Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic.

Published byRafe McKenzie Modified over 6 years ago

Similar presentations

Presentation on theme: "Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic."— Presentation transcript:

1 Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia by Farhad Ravandi, Susan O'Brien, Rebecca Garris, Stefan H. Faderl, Deborah A. Thomas, Jan A. Burger, Alessandra Ferrajoli, Elias Jabbour, Jorge E. Cortes, and Hagop M. Kantarjian Blood Volume 122(21): November 15, 2013 ©2013 by American Society of Hematology

2 Susan O'Brien et al. Blood 2013;122:3914
©2013 by American Society of Hematology

3 Susan O'Brien et al. Blood 2013;122:3914
©2013 by American Society of Hematology

Download ppt "Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic."

Similar presentations

Long-term Outcome after hyper-CVAD and Imatinib for De Novo or Minimally Treated Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph-ALL)

Long-term Outcome after hyper-CVAD and Imatinib for De Novo or Minimally Treated Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph-ALL)
Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia by Robin Foà, Antonella Vitale,

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia by Robin Foà, Antonella Vitale,
The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia by Alessandra Ferrajoli, Michael J. Keating,

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia by Alessandra Ferrajoli, Michael J. Keating,
Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.

Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
Hippo Pathway (HP) Activity In Acute Myelogenous Leukemia (AML): Different Prognostic Implications Of TAZ versus YAP Inactivation By Phosphorylation by.

Hippo Pathway (HP) Activity In Acute Myelogenous Leukemia (AML): Different Prognostic Implications Of TAZ versus YAP Inactivation By Phosphorylation by.
Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell.

Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell.
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.
Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21)‏ by Anthony V. Moorman, Susan.

Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21)‏ by Anthony V. Moorman, Susan.
Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,

Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,
Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group by.

Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group by.
Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib by Keyur P. Patel, Kate J. Newberry, Rajyalakshmi.

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib by Keyur P. Patel, Kate J. Newberry, Rajyalakshmi.

Similar presentations

Ads by Google